C L I N I C
T H E
I N
T
HE CLINIC IS THE ARM OF THE MMRF PRECISION MEDICINE MODEL that aims to accelerate clinical trials to rapidly
bring new treatments to patients. The Multiple Myeloma Research Consortium (MMRC), a unique collaborative model
of 22 centers in the United States and Canada, evaluates novel agents and combinations for their safety, efficacy and
feasibility in phase 1 and 2 clinical trials.
2016 Active Clinical Trials
Novel
CB-5083
Relapsed
or R/R
ABT 199
Selinexor/
Kyprolis/Dex
New Dx./
Transplant
Key
Phase 1
Antibodies & Immune
Phase 1/2
PI's & IMID's
Phase 2
Molecularly Targeted
Ibrutinib/
Atezo/
Empliciti/
Pomalyst/
Mdm2i/
Kyprolis
Revlimid
Velcade/
Kyprolis/Dex
Ixa 17p
Selinexor/
SAR
Dex
650984/
Kyprolis
Pomalyst/Dex
deleted
Empliciti/
Pomalyst/
Pomalyst/Dex
Ninlaro/
SAR 650984
Atezo/Post-Transplant
PINR
EMD/PCL
Ninlaro/
Revlimid/
Dex
Transplant *
* This study is currently being conducted at two different sites: Washington University and University of Chicago.
10
T H E M M R F.ORG